Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Reticulocyte Count

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    79 result(s) found for: Reticulocyte Count. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2019-003830-17 Sponsor Protocol Number: ACH228-110 Start Date*: 2020-09-16
    Sponsor Name:Achillion Pharmaceuticals, Inc., a wholly owned subsidiary of Alexion Pharmaceuticals Inc.
    Full Title: A Phase 2 Open-Label Proof of Concept Study to Assess the Efficacy, Safety, and Pharmacokinetics of the Oral Factor D (FD) Inhibitor ACH-0145228 in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patient...
    Medical condition: Paroxysmal Nocturnal Hemoglobinuria (PNH)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10034042 Paroxysmal nocturnal haemoglobinuria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IT (Prematurely Ended) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-004472-21 Sponsor Protocol Number: PCS_03_16 Start Date*: 2017-08-31
    Sponsor Name:Pieris Pharmaceuticals GmbH
    Full Title: Phase IIa study to evaluate the safety, pharmacokinetics, and pharmacodynamics of repeated administrations over 4 weeks of the hepcidin antagonist PRS-080#022-DP in anemic chronic kidney disease pa...
    Medical condition: Anemia of chronic disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10054310 Anemia of chronic disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2018-004220-11 Sponsor Protocol Number: APL2-308 Start Date*: 2019-07-23
    Sponsor Name:Apellis Pharmaceuticals, Inc.
    Full Title: A Phase 3, Randomized, Multicenter, Open-Label, Controlled Study to Evaluate the Efficacy and Safety of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
    Medical condition: Paroxysmal Nocturnal Hemoglobinuria (PNH)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004857 10055629 Paroxysmal nocturnal hemoglobinuria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-003829-18 Sponsor Protocol Number: ALXN2040-PNH-301 Start Date*: 2020-11-04
    Sponsor Name:Alexion Pharmaceuticals Inc.
    Full Title: A Phase 3 Study of Danicopan (ALXN2040) as Add-on Therapy to a C5 Inhibitor (Eculizumab or Ravulizumab) in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Have Clinically Evident Extravascula...
    Medical condition: Patients with Paroxysmal Nocturnal Hemoglobinuria Who Have Clinically Evident Extravascular Hemolysis (EVH)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10034042 Paroxysmal nocturnal haemoglobinuria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) GB (GB - no longer in EU/EEA) NL (Ongoing) PL (Completed) IT (Ongoing) GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-002155-11 Sponsor Protocol Number: B5411003 Start Date*: 2021-06-09
    Sponsor Name:Pfizer Inc.
    Full Title: A MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO ACCESS THE EFFICACY AND SAFETY OF PF-06462700 ADMINISTERED INTRAVENOUSLY AT 40 MG/KG/DAY FOR 4 DAYS IN JAPANESE PARTICIPANTS WITH MODERATE AND ABOVE A...
    Medical condition: Moderate and above aplastic anemia
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-004268-36 Sponsor Protocol Number: APL2-302 Start Date*: 2018-10-01
    Sponsor Name:Apellis Pharmaceuticals, Inc.
    Full Title: A Phase III, Randomized, Multi-Center, Open-Label, Active-Comparator Controlled Study to Evaluate the Efficacy and Safety of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
    Medical condition: PNH is an acquired, rare, clonal, non-malignant hematologic disease characterized by complement-mediated RBC hemolysis with or without hemoglobinuria, an increased susceptibility to thrombotic epis...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10055629 Paroxysmal nocturnal hemoglobinuria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) ES (Completed) NL (Completed) FR (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-000174-19 Sponsor Protocol Number: 9345 Start Date*: 2015-01-27
    Sponsor Name:Universitätsklinikum Ulm
    Full Title: Efficacy and Safety of Eltrombopag in Patients with Acquired Moderate Aplastic Anemia (EMAA) who are treated with Ciclosporin A Prospective Randomized Multicenter Study comparing Thrombopoetin-Re...
    Medical condition: Moderate Aplastic Anemia (MAA)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003858-85 Sponsor Protocol Number: HFIRONT Start Date*: 2020-02-24
    Sponsor Name:Medical University Innsbruck
    Full Title: Randomized double-blind explorative controlled clinical trial analyzing the effects of ferric carboxymaltose in patients with iron deficiency and chronic heart failure
    Medical condition: This is a randomized double-blind explorative controlled clinical Trial that analyses the effects of 1000mg ferric carboxymaltose in patients with chronic heart failure and iron deficiency.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-002218-39 Sponsor Protocol Number: AFX01-04 Start Date*: 2005-08-16
    Sponsor Name:Affymax, Inc.
    Full Title: A Phase 2, Open-label, Multi-center, Sequential Dose Finding Study of the Safety, Pharmacodynamics, and Pharmacokinetics of Multiple Doses of AF37702 Injection (HematideTM) in Chronic Kidney Diseas...
    Medical condition: Anaemia in patients with chronic kidney disease not on dialysis (pre-dialysis patients).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-005140-16 Sponsor Protocol Number: APL2-202 Start Date*: 2018-07-18
    Sponsor Name:Apellis Pharmaceuticals
    Full Title: A Phase IIa, Open Label, Multiple Dose Study to Assess the Safety, Efficacy and Pharmacokinetics of Subcutaneously Administered APL-2 in Subjects with Paroxysmal Nocturnal Hemoglobinuria (PNH)
    Medical condition: Paroxysmal Nocturnal Hemoglobinuria (PNH)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004857 10055629 Paroxysmal nocturnal hemoglobinuria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-003354-10 Sponsor Protocol Number: AFX01-05 Start Date*: 2005-10-26
    Sponsor Name:Affymax, Inc.
    Full Title: A Phase 2, Open-Label, Multi-Center Dose Escalation Study of the Safety, Pharmacodynamics, and Pharmacokinetics of Subcutaneously Administered AF37702 Injection (HematideTM) in Anemic Cancer Patien...
    Medical condition: Anemia in cancer patients receiving chemotherapy.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2012-001525-27 Sponsor Protocol Number: SNOXH94C201 Start Date*: 2012-07-19
    Sponsor Name:NOXXON Pharma AG
    Full Title: Phase IIa study to characterize the effects of the Spiegelmer® NOX-H94 on anemia of chronic disease in patients with cancer
    Medical condition: anemia of chronic disease in patients with cancer
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004864 10007050 Cancer LLT
    16.0 100000004851 10054310 Anemia of chronic disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) BG (Completed)
    Trial results: View results
    EudraCT Number: 2020-003485-39 Sponsor Protocol Number: NN7533-4470 Start Date*: 2022-07-19
    Sponsor Name:Novo Nordisk A/S
    Full Title: A multicentre trial evaluating the efficacy and safety of oral decitabine-tetrahydrouridine (NDec) in patients with sickle cell disease
    Medical condition: Sickle cell disease
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10040644 Sickle cell disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Ongoing) IT (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-004790-32 Sponsor Protocol Number: 204836 Start Date*: 2016-03-07
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A 29-day, randomized, double-blinded, placebo-controlled, parallel-group, multi-center study to evaluate the efficacy, safety and pharmacokinetics of three-times weekly dosing of GSK1278863 in hemo...
    Medical condition: Anemia associated with chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004851 10002272 Anemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-004209-15 Sponsor Protocol Number: GBT440-007 Start Date*: 2019-01-08
    Sponsor Name:Global Blood Therapeutics, Inc.
    Full Title: A Phase 2a, Open-label, Single and Multiple Dose Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Treatment Effect of GBT440 in Pediatric Participants with Sickle Cell Disease
    Medical condition: Sickle Cell Disease
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10040644 Sickle cell disease PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2011-003233-34 Sponsor Protocol Number: 11048 Start Date*: 2012-01-19
    Sponsor Name:University of Nottingham
    Full Title: The effect of intravenous iron on postoperative transfusion requirements in hip fracture patients – a pilot study
    Medical condition: Anaemia following hip fracture
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-000031-28 Sponsor Protocol Number: CLKA651X2202 Start Date*: 2019-04-11
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, active-controlled, patient and investigator-masked, multiple dose proof-of-concept study of intravitreal LKA651 in patients with diabetic macular edema
    Medical condition: diabetic macular edema
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10057934 Diabetic macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2017-003652-22 Sponsor Protocol Number: INCB50465-206 Start Date*: 2018-05-18
    Sponsor Name:Incyte Corporation
    Full Title: A Phase 2, Open-Label Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia
    Medical condition: Autoimmune Hemolytic Anemia (AIHA), immunohemolytic anemia, autoimmune hemolytic anemia, immune complex hemolytic anemia. Warm AIHA, Cold AIHA
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10003825 Autoimmune hemolytic anemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) AT (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-001245-13 Sponsor Protocol Number: 4LB-LEO-P Start Date*: 2022-03-03
    Sponsor Name:4Living Biotech SAS
    Full Title: A randomized, double-blind, placebo-controlled, two parallel groups, international multicenter trial to evaluate the effect of Plerixafor in acute respiratory failure related to COVID-19 (LEONARDO)
    Medical condition: Severe COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10084268 COVID-19 PT
    23.1 10021881 - Infections and infestations 10084380 COVID-19 pneumonia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) NL (Prematurely Ended) BG (Prematurely Ended) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-001190-24 Sponsor Protocol Number: BAY85-3934/15653 Start Date*: 2013-11-12
    Sponsor Name:Bayer AG
    Full Title: A controlled, parallel group, open-label, multicenter extension study to investigate efficacy and safety of oral BAY 85-3934 and darbepoetin alfa comparator in the long term treatment of anemia in ...
    Medical condition: Anaemia of Chronic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004851 10058123 Renal anaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) IT (Completed) HU (Completed) ES (Completed) BG (Prematurely Ended) PL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 02:20:17 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA